Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 23, 2026

A Strategy for Sensitive, Large Scale Quantitative Metabolomics
14:18

A Strategy for Sensitive, Large Scale Quantitative Metabolomics

Published on: May 27, 2014

S-carboxymethyl-L-cysteine.

Steve C Mitchell1, Glyn B Steventon

  • 1Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, United Kingdom.

Drug Metabolism Reviews
|April 14, 2012
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of the oxime HI-6 dimethanesulphonate in the treatment of guinea-pigs exposed to the nerve agents GB and GD.

Toxicology letters·2023
Same author

Phenylalanine monooxygenase and the 'sulfoxidation polymorphism'; the salient points.

Drug metabolism and personalized therapy·2022
Same author

S-Carboxymethyl-l-cysteine: a multiple dosing study using pharmacokinetic modelling.

Xenobiotica; the fate of foreign compounds in biological systems·2021
Same author

Phenylalanine 4-monooxygenase: the "sulfoxidation polymorphism".

Xenobiotica; the fate of foreign compounds in biological systems·2019
Same author

Drug S-oxidation and phenylalanine hydroxylase: a biomarker for neurodegenerative susceptibility in Parkinson's disease and amyotrophic lateral sclerosis.

Drug metabolism and personalized therapy·2019
Same author

Corrigendum to "Phenylalanine hydroxylase: A biomarker of disease susceptibility in Parkinson's disease and amyotrophic lateral sclerosis" [Med. Hypotheses 118 (2018) 29-33].

Medical hypotheses·2018
Same journal

Humanized mouse models for drug metabolism and drug transport: a systematic review.

Drug metabolism reviews·2026
Same journal

Drug transporters in drug disposition - highlights from the year 2025.

Drug metabolism reviews·2026
Same journal

Herbal supplements and anti-tuberculosis therapy: unlocking hidden interactions for better multidrug-resistant tuberculosis management.

Drug metabolism reviews·2026
Same journal

Identification and characterization of a novel aldehyde metabolite of WIN18,446 and associated WIN18,446-ALDH1A2 protein adducts using mass spectrometry.

Drug metabolism reviews·2026
Same journal

Pharmacomicrobiomics in precision pharmacotherapy: bidirectional microbial-drug interactions as a key determinant of therapeutic response.

Drug metabolism reviews·2026
Same journal

Population pharmacokinetics of levofloxacin: a systematic review.

Drug metabolism reviews·2026
See all related articles

S-carboxymethyl-L-cysteine, a cysteine derivative, has a complex metabolism influenced by genetics and time of day. This variability may explain differing patient responses to its use in respiratory medicine.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Respiratory Medicine

Background:

  • S-carboxymethyl-L-cysteine (SCMC) is a derivative of the amino acid cysteine.
  • SCMC has been utilized for nearly 80 years, finding a specific clinical application in respiratory medicine.
  • Early metabolic studies suggested a simple metabolic pathway for SCMC.

Purpose of the Study:

  • To review the literature on the metabolic fate of S-carboxymethyl-L-cysteine.
  • To provide a comprehensive overview of SCMC metabolism.
  • To explore factors influencing SCMC's therapeutic efficacy.

Main Methods:

  • Literature review of SCMC metabolism.
  • Analysis of studies on intermediary metabolism interactions.
  • Examination of research on genetic and circadian influences on metabolism.

More Related Videos

Targeting Cysteine Thiols for in Vitro Site-specific Glycosylation of Recombinant Proteins
11:25

Targeting Cysteine Thiols for in Vitro Site-specific Glycosylation of Recombinant Proteins

Published on: October 4, 2017

Synthesis of Protein Bioconjugates via Cysteine-maleimide Chemistry
09:14

Synthesis of Protein Bioconjugates via Cysteine-maleimide Chemistry

Published on: July 20, 2016

Related Experiment Videos

Last Updated: May 23, 2026

A Strategy for Sensitive, Large Scale Quantitative Metabolomics
14:18

A Strategy for Sensitive, Large Scale Quantitative Metabolomics

Published on: May 27, 2014

Targeting Cysteine Thiols for in Vitro Site-specific Glycosylation of Recombinant Proteins
11:25

Targeting Cysteine Thiols for in Vitro Site-specific Glycosylation of Recombinant Proteins

Published on: October 4, 2017

Synthesis of Protein Bioconjugates via Cysteine-maleimide Chemistry
09:14

Synthesis of Protein Bioconjugates via Cysteine-maleimide Chemistry

Published on: July 20, 2016

Main Results:

  • Later investigations reveal complex interactions of SCMC with intermediary metabolism.
  • Emerging evidence suggests SCMC metabolism is influenced by genetic polymorphisms and circadian rhythms.
  • Conflicting reports on SCMC's therapeutic efficacy may be linked to these metabolic variations.

Conclusions:

  • SCMC's metabolism is more intricate than previously thought.
  • Individual metabolic differences, including genetic and temporal factors, likely impact SCMC's clinical effectiveness.
  • Further research is needed to elucidate these complex metabolic pathways and optimize SCMC therapy.